Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHORD: Cholesterol Lowering and Residual Risk in Type 2 Diabetes
NCT04369664Phase 4Completed
- Sponsor
- NYU Langone Health
- Start
- Aug 2020
- Primary completion
- Sep 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of evolocumab in hypercholesterolemia, sponsored by NYU Langone Health. Started Aug 2020; status: completed.
02
Drugs
evolocumab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT04369664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369664.